BMF-219 is the first irreversible covalent menin inhibitor to enter the clinicPhase I trial is enrolling patients with relapsed/refractory acute leukemias, including those with MLL1/KMT2A…
BMF-219 displays global disruption of menin, highlighting ‘219’s novel mechanism of actionMolecule elicits broad impact on the complexes surrounding menin, resulting in strong modulation of…